Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Table 3
Accumulative adverse events during the 52 weeks of treatment.
Adverse event
Treatment group (n = 136)
Control group (n = 135)
value
Fatigue
28 (20.6)
25 (18.5)
0.760
Upper abdominal pain
21 (15.4)
19 (14.1)
0.864
Diarrhea
24 (17.6)
22 (16.3)
0.872
Nausea
21 (15.4)
22 (16.3)
0.869
Dyspepsia
33 (24.3)
35 (25.9)
0.781
Dizziness
12 (8.8)
15 (11.1)
0.550
Itching
24 (17.6)
29 (21.5)
0.447
Headache
20 (14.7)
16 (11.9)
0.592
Cough
8 (5.9)
9 (6.7)
0.808
Serious adverse event
0 (0)
0 (0)
Discontinuation due to adverse event
2 (1.4)
1 (0.7)
1.000
Death
0 (0)
0 (0)
Values in parentheses are percentages unless indicated otherwise.
